机构:[1]Department of Urology, China Aerospace Science & Industry Corporation 731 Hospital, Feng Tai District, Beijing, China[2]Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.临床科室泌尿外科河北医科大学第四医院
第一作者机构:[1]Department of Urology, China Aerospace Science & Industry Corporation 731 Hospital, Feng Tai District, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Urology, China Aerospace Science & Industry Corporation 731 Hospital, Feng Tai District, Beijing, China[*1]Department of Urology, China Aerospace Science & Industry Corporation 731 Hospital, No. 3, Zhen Gang Nan Li, Yun Gang, Feng Tai District, 100074, Beijing, China
推荐引用方式(GB/T 7714):
Fu Taozhu,Zhang Lianfeng,Zuo Meini,et al.FCGR2A as one novel potential target for poor survival prognosis of clear cell renal cell carcinoma[J].MEDICINE.2023,102(11):doi:10.1097/MD.0000000000033324.
APA:
Fu Taozhu,Zhang Lianfeng,Zuo Meini,Li Feng,Shi Changjin&Chen Hongrun.(2023).FCGR2A as one novel potential target for poor survival prognosis of clear cell renal cell carcinoma.MEDICINE,102,(11)
MLA:
Fu Taozhu,et al."FCGR2A as one novel potential target for poor survival prognosis of clear cell renal cell carcinoma".MEDICINE 102..11(2023)